AbSci Corp (ABSI) News

AbSci Corp (ABSI): $1.86

0.02 (+0.82%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add ABSI to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#350 of 380

in industry

Filter ABSI News Items

ABSI News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ABSI News Highlights

  • For ABSI, its 30 day story count is now at 4.
  • Over the past 12 days, the trend for ABSI's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about ABSI are DRUG, WASH and BEAT.

Latest ABSI News From Around the Web

Below are the latest news stories about ABSCI CORP that investors may wish to consider to help them evaluate ABSI as an investment opportunity.

Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates

Absci Corporation (ABSI) delivered earnings and revenue surprises of -8.33% and 41.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 15, 2023

Absci Reports Business Updates and First Quarter 2023 Financial and Operating Results

Commenced work plan preparations and expect to initiate program work during second quarter leveraging Absci's generative AI drug creation platform for Phase II candidate Achieved rapid advancements of generative AI drug creation platform, continually building on prior breakthroughs VANCOUVER, Wash. and NEW YORK, May 15, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today reported financial and operating results for the quarter ended March 31, 2

Yahoo | May 15, 2023

University of Oxford’s Kennedy Institute of Rheumatology Partners with Absci to Accelerate AI-Driven Immunotherapies

Absci will apply its generative AI platform to The Kennedy Institute’s immunology biorepository to speed the discovery and development of multiple therapiesVANCOUVER, Wash. and OXFORD, UK, May 11, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, and the University of Oxford’s Kennedy Institute of Rheumatology, a biomedical research center developing new therapies for chronic inflammatory and musculoskeletal conditions, today announced a partnershi

Yahoo | May 11, 2023

Absci Corporation (ABSI) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Absci Corporation (ABSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | May 3, 2023

Absci to Participate in the 22nd Annual Needham Virtual Healthcare Conference

VANCOUVER, Wash. and NEW YORK, April 06, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the upcoming 22nd Annual Needham Virtual Healthcare Conference. Absci management is scheduled to present on Thursday, April 20th at 1:30 p.m. Eastern Time (10:30 a.m. Pacific Time). Interested parties may access a live and archived webcast on the company’s investor relations website at: investors.absci.com.

Yahoo | April 6, 2023

Absci Partners with Bioinformatics Company M2GEN to Accelerate Drug Creation for Oncology

Absci’s generative AI platform will use M2GEN’s industry-leading clinicogenomic database with the aim of creating better cancer treatments fasterVANCOUVER, Wash. and TAMPA, Fla., April 04, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, and M2GEN, an oncology bioinformatics company with the most advanced lifetime-consented clinicogenomics data to accelerate discovery research, today announced a partnership to create new cancer medicines and bring

Yahoo | April 4, 2023

Absci Full Year 2022 Earnings: Revenues Disappoint

Absci ( NASDAQ:ABSI ) Full Year 2022 Results Key Financial Results Net loss: US$104.9m (loss widened by 1.6% from FY...

Yahoo | April 1, 2023

Absci Reports Fourth Quarter and Full Year 2022 Financial and Operating Results

Advanced platform achieving multiple industry breakthroughs including creation and validation of de novo antibodies using zero-shot generative AI 10 new Active Programs in 2022, exceeding full-year guidance VANCOUVER, Wash. and NEW YORK, March 30, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), the generative AI drug creation company, today reported financial and operating results for the fourth quarter and year ended December 31, 2022. "2022 was a transformational year for Absci that

Yahoo | March 30, 2023

Absci to Participate in the B. Riley Securities' Life Sciences Tools Conference - Proteomics Setting the Blueprint for Innovative Drug Creation

VANCOUVER, Wash. and NEW YORK, March 23, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating virtually in the upcoming B. Riley Securities' Life Sciences Tools Conference - Proteomics Setting the Blueprint for Innovative Drug Creation. Absci’s management is scheduled to participate in a panel discussion and a fireside chat, the details of which are below: Panel: How to translate insights from proteomi

Yahoo | March 23, 2023

Absci to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

VANCOUVER, Wash. and NEW YORK, March 07, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating virtually in the upcoming KeyBanc Capital Markets Life Sciences & MedTech Investor Forum. Absci management is scheduled to participate in a fireside chat on Tuesday March 21st at 3:00 p.m. Eastern Time (12:00 p.m. Pacific Time). Interested parties may access a live and archived webcast on the company’s investo

Yahoo | March 7, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6387 seconds.